|
Thursday December 1, 2011 |
|
| |
|
|
| 13.30 |
XVII European Charcot Foundation Lecture |
Montalban, Barcelona |
| Towards Treatment of Persons with Multiple Sclerosis: on detour and access |
|
|
|
| 14.30 – 15.00 |
Discussion |
|
|
|
|
|
SESSION I |
|
|
Rationale for personalized treatment in face of disease complexity |
|
|
|
|
| 15.00 |
Natural course, disease complexity and the differential diagnosis of inflammatory brain diseases |
Edan, Rennes |
|
|
|
| 15.20 |
Pathology: the mechanisms during early stages of the disease and later |
Lassmann, Vienna |
|
| 15.40 |
Genetics and environment. The natural course of Multiple Sclerosis and the personal history of the illness. Data from epidemiology |
Ebers, Oxford |
|
|
|
| 16.00 |
Personalized medicine: taking shared decision making seriously |
Spreeuwenberg, Maastricht |
|
|
|
| 16.20 – 16.50 |
Discussion |
|
|
|
|
| 16.50 – 17.20 |
Coffee break |
|
|
|
|
| 17.30 – 19.00 |
Integrated Satellite Symposium Merck Serono |
|
|
"Leveraging established therapies and modern data for individualized MS treatment” |
|
| Chair: X. Montalban K. Selmaj |
|
|
|
| 17.30 |
Treatment tailoring and long term treatment benefits |
Uitdehaag, Amsterdam |
|
|
|
| 17.50 |
Individualized treatment from the first demyelinating event |
Freedman, Ottawa |
|
|
|
| 18.10 |
Impact of conventional and non-conventional MRI technology on patient management |
Speaker invited |
|
|
|
| 19.00 – 20.00 |
Welcome Reception |
|
|
|
|
|
Friday December 2, 2011 |
|
| |
|
|
| |
Session II |
|
|
Tools for prognosis |
|
|
|
|
| 08.30 |
MRI. Early activity, damage and progress of the disease |
Fazekas, Graz |
|
|
|
| 08.50 |
Future MRI Tools |
Filippi, Milan |
|
|
|
| 09.10 |
Prognostic possibilities of neurophysiology |
Leocani, Milan |
|
|
|
| 09.30 |
Biomarkers for damage, repair and side effects of treatment in MS prognosis |
Giovannoni, London |
|
|
|
| 09.50 |
Integrating the tools for an individualized prognosis |
Fernandez, Malaga |
|
|
|
| 10.10 – 10.30 |
Discussion |
|
|
|
|
| 10.30 – 11.00 |
Coffee break |
|
|
|
|
| 11.00 – 12.30 |
Integrated Satellite Symposium TEVA |
|
|
"Guiding therapeutic decisions in MS: is it possible?” |
|
|
Chair: J. Palace G. Comi |
|
|
|
|
| 11.00 |
Defining the patient phenotype |
Gold, Bochum |
|
|
|
| 11.20 |
Targeting different aspects of disease pathology |
Brück, Göttingen |
|
|
|
| 11.40 |
Drug response markers to Glatiramer acetate |
Centonze, Rome |
|
|
|
| 12.00 – 12.30 |
Discussion |
|
|
|
|
| 12.30 – 14.00 |
Lunch |
|
|
|
|
|
Session III |
|
|
Treatment heterogeneity, targets and risks |
|
|
|
|
| 14.00 |
Viability of targets: How to tackle pathogenetic heterogeneity as an obstacle for treatment |
Hohlfeld, Munich |
|
|
|
| 14.20 |
Combination therapies: the rationale of addition and synergy in personalized treatment |
Comi, Milan |
|
|
|
| 14.40 |
Risks in Multiple Sclerosis treatments on immune competence and neuroprotective autoimmunity in patients undergoing immunotherapy |
Gold, Bochum |
|
|
|
| 15.00 |
General risks of Multiple Sclerosis treatment |
Du Pasquier, Lausanne |
|
|
|
| 15.20 – 15.30 |
Discussion |
|
|
|
|
| 15.30 – 16.00 |
Coffee break |
|
|
|
|
|
Session IV |
|
|
Treatment in practice |
|
|
|
|
| 16.00 |
Decision on CIS treatment |
Vass, Vienna |
|
|
|
| 16.20 |
MRI and treatment decisions in daily practice |
Brassat, Toulouse |
|
|
|
| 16.40 |
Interferon-beta. To start and to stop |
Derfuss, Basel |
|
|
|
| 17.00 |
Personalized and participatory medicine in MS. How to translate pharmogenomics and genetics? |
Miller, Haifa |
|
|
|
| 17.20 |
Antibodies to interferon-beta and other treatments |
Soelberg Soerensen, Copenhagen |
|
|
|
| 17.40 |
Perspectives of ex-vivo testing for treatment responders: a key to personalized medicine in MS |
Hemmer, Munich |
|
|
|
| 18.00 |
Can biomarkers be selected to predict the course of CIS for every day practice |
Sastre-Garriga, Barcelona |
|
|
|
| 18.20 – 18.50 |
Discussion |
|
|
|
|
| 20.30 |
Speakers' Dinner |
|
|
|
|
|
Saturday December 3, 2011 |
|
| |
|
|
| |
Session V |
|
|
Partnership |
|
|
|
|
| 08.30 |
Partnership and consent in Multiple Sclerosis treatment |
Palace, Oxford |
|
|
|
| 08.50 |
Informed shared decision making and patient autonomy |
Heesen, Hamburg |
|
|
|
| 09.10 |
A patients perspective of partnership in the treatment of Multiple Sclerosis |
Von Pückler, Frankfurt am Main |
|
|
|
| 09.30 – 10.00 |
Coffee break |
|
|
|
|
| 10.00 |
How to implement partnership in every day clinical practice |
Langdon, London |
|
|
|
| 10.20 |
Measuring results of partnership treatment decisions. On new trial designs |
Uitdehaag, Amsterdam |
|
|
|
|
Session VI |
|
|
Personalized Treatment, Partnership and disease complexity |
|
|
| 10.40 – 12.10 |
Round Table Discussion |
|
| Guided by E. Havrdova and A. Boyko |
|
|
|
| 12.10 – 12.40 |
European Charcot Foundation Young Investigators Awards |
|
|
| 12.40 |
Closure |
|
|
|
|
| 13.00 – 14.00 |
Lunch |
|
Download programme